|
Schlusskurs
Swiss Exchange
|
||
| - CHF | - |
|
| 22.07.24 | EU-Kommission verpflichtet Pharmakonzern Vifor zu Gegendarstellung | DP |
| 19.04.24 | Europäische Kommission bittet um Rückmeldung zu den Wettbewerbsverpflichtungen von Vifor Pharma | MT |
Hauptkonkurrenten
| % | % 5 Tage | Veränd. 1 Monat | Veränd. 3 Monate | % 1. Jan. | Perf. 1 Jahr | Perf. 3 Jahre | Veränd. 5 Jahre | Veränd. 10 Jahre | Marktkap.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -3.76% | -0.65% | +19.39% | +16.66% | +26.99% | +47.41% | +140.35% | +414.99% | +1’782.65% | 1’216 Mrd. | |
| -1.45% | -1.05% | +7.67% | +5.72% | +31.59% | +46.41% | +79.94% | +66.63% | +136.57% | 656 Mrd. | |
| -2.24% | -0.88% | +8.46% | +17.08% | +26.15% | +32.97% | +103.82% | +145.98% | +414.35% | 509 Mrd. | |
| -2.28% | -4.96% | +9.61% | +5.13% | +16.82% | +44.57% | +61.67% | +4.77% | +70.70% | 384 Mrd. | |
| -2.27% | +0.42% | +5.30% | +14.50% | +39.60% | +74.12% | +42.14% | +80.05% | +149.81% | 362 Mrd. | |
| -2.31% | -2.00% | +11.88% | +4.73% | +19.62% | +28.63% | +55.63% | +72.36% | +89.18% | 311 Mrd. | |
| -3.07% | -2.23% | +14.13% | +15.17% | -1.03% | +6.34% | +32.81% | +46.27% | +208.05% | 293 Mrd. | |
| -3.80% | -0.10% | +14.22% | +12.86% | +40.63% | +43.90% | +70.56% | +115.32% | +239.94% | 249 Mrd. | |
| -3.96% | +1.18% | +15.86% | +27.18% | +36.52% | +36.70% | +105.38% | +152.67% | +131.35% | 208 Mrd. | |
| -0.53% | +1.71% | +10.22% | -7.82% | -16.79% | -11.83% | -61.40% | -26.61% | +135.25% | 180 Mrd. | |
| -2.96% | -0.23% | +9.01% | +15.77% | +20.00% | +21.41% | -4.41% | -38.53% | -0.40% | 170 Mrd. | |
| -1.19% | +0.46% | +7.75% | +11.89% | +19.66% | +30.10% | +44.21% | +181.31% | +587.06% | 138 Mrd. | |
| -1.65% | +2.83% | +7.35% | -0.79% | +17.04% | +35.85% | +19.52% | +6.19% | +23.76% | 129 Mrd. | |
| +0.24% | +9.29% | +17.10% | +22.20% | +30.69% | +26.98% | +136.77% | +383.56% | +719.82% | 124 Mrd. | |
| -2.54% | +3.25% | +16.60% | +10.79% | -0.47% | -3.83% | -3.07% | -6.67% | +13.92% | 114 Mrd. | |
| -6.55% | +8.39% | +18.82% | +329.22% | +718.79% | +924.87% | +211.44% | +1.89% | - | 96.4 Mrd. | |
| -2.25% | -0.24% | +4.81% | -4.44% | +1.43% | +4.05% | +31.71% | -4.99% | -4.43% | 102 Mrd. | |
| -2.98% | +10.28% | +24.29% | +17.48% | +16.98% | +40.16% | +10.53% | +47.64% | +164.48% | 90.6 Mrd. | |
| -2.16% | -2.31% | +6.33% | +1.83% | +20.55% | +34.00% | +0.82% | -29.01% | +60.13% | 73.36 Mrd. | |
| Durchschnitt | -2.23% | +3.19% | +12.04% | +27.11% | +56.04% | +76.99% | +56.76% | +84.94% | +273.45% | 284.43 Mrd. | |
| Nach Marktkapitalisierung gewichteter Durchschnitt | -2.55% | +1.23% | +12.50% | +17.48% | +35.65% | +53.11% | +77.58% | +150.41% | +554.37% |
- Börse
- Aktien
- A2DRZ4 Aktie
- Aktie
- Sektor Vifor Pharma
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
